loading
前日終値:
$15.81
開ける:
$15.98
24時間の取引高:
431.87K
Relative Volume:
0.41
時価総額:
$798.76M
収益:
-
当期純損益:
$-156.39M
株価収益率:
-4.3279
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
+1.11%
1か月 パフォーマンス:
+33.82%
6か月 パフォーマンス:
+82.46%
1年 パフォーマンス:
+3.74%
1日の値動き範囲:
Value
$15.83
$16.09
1週間の範囲:
Value
$15.20
$16.23
52週間の値動き範囲:
Value
$7.30
$16.32

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
名前
Kalvista Pharmaceuticals Inc
Name
セクター
Healthcare (1165)
Name
電話
(857) 999-0075
Name
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
職員
270
Name
Twitter
@kalvista
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
KALV's Discussions on Twitter

KALV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
15.99 757.80M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.00 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.62 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
572.60 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.93 29.19B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-31 開始されました JMP Securities Mkt Outperform
2025-01-07 開始されました TD Cowen Buy
2024-12-18 開始されました BofA Securities Buy
2020-06-15 開始されました H.C. Wainwright Buy
2019-07-29 開始されました SVB Leerink Outperform
2019-03-20 開始されました Needham Buy
2018-10-30 開始されました Jefferies Buy
2018-09-21 開始されました Cantor Fitzgerald Overweight
2017-08-31 開始されました BTIG Research Buy
すべてを表示

Kalvista Pharmaceuticals Inc (KALV) 最新ニュース

pulisher
04:14 AM

KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com

04:14 AM
pulisher
Jul 22, 2025

What drives KalVista Pharmaceuticals Inc. stock priceOutstanding yields - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about KalVista Pharmaceuticals Inc. stockSuperior trading gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista's Ekterly OK'd as on-demand HAE swelling attack treatment in UK - Angioedema News

Jul 17, 2025
pulisher
Jul 16, 2025

(KALV) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Jul 16, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

MHRA approves Ekterly to treat HAE - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Jul 14, 2025
pulisher
Jul 13, 2025

Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 11, 2025

Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista price target raised to $27 from $19 at Citizens JMP - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Shares Fall After Fiscal 2025 Results - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30Earnings Summary - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharmaceuticals IncFDA approves Kalvista's Ekterly for hereditary angioedema - MarketScreener

Jul 10, 2025

Kalvista Pharmaceuticals Inc (KALV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.70
price up icon 4.20%
$35.91
price down icon 0.52%
$101.86
price down icon 0.93%
$27.68
price up icon 4.30%
$113.71
price up icon 2.09%
biotechnology ONC
$295.83
price up icon 0.07%
大文字化:     |  ボリューム (24 時間):